BeOne Medicines Ltd ADR(ONC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | 60.89 | EPS (ttm) | 5.69 | Insider Own | 0.53% | Shs Outstand | 104.2M | Perf Week | -4.46% |
| Market Cap | 36.13B | Forward P/E | 34.12 | EPS next Y | 36.39% | Insider Trans | -64.15% | Shs Float | 103.7M | Perf Month | -3.49% |
| Enterprise Value | 32.92B | PEG | 0.46 | EPS next Q | 1.9 | Inst Own | 33.31% | Short Float | 1.37% | Perf Quarter | 33.13% |
| Income | 0.66B | P/S | 5.88 | EPS this Y | 183.14% | Inst Trans | 0.53% | Short Ratio | 3.77 | Perf Half Y | 21.45% |
| Sales | 6.14B | P/B | 7.57 | EPS next 5Y | 73.84% | ROA | 8.49% | Short Interest | 1.42M | Perf YTD | 14.05% |
| Book/sh | 45.78 | P/C | 6.87 | EPS past 3/5Y | - | ROE | 14.7% | 52W High | -10.05% ($385.22) | Perf Year | 3.23% |
| Cash/sh | 50.44 | P/FCF | 27.1 | Sales past 3/5Y | 55.88% 76.88% | ROIC | 9.5% | 52W Low | 36.45% ($253.95) | Perf 3Y | 65.6% |
| Dividend Est. | - | EV/EBITDA | 30.46 | EPS Y/Y TTM | 449.53% | Gross Margin | 86.76% | Volatility(W/M) | 1.98% 2.09% | Perf 5Y | -1.56% |
| Dividend TTM | - | EV/Sales | 5.36 | Sales Y/Y TTM | 34.39% | Oper. Margin | 15.06% | ATR (14) | 9.42 | Perf 10Y | 1044.35% |
| Dividend Ex-Date | - | Quick Ratio | 3.06 | EPS Q/Q | 143.77% | Profit Margin | 10.7% | RSI (14) | 45.41 | Recom | 1.28 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.4 | Sales Q/Q | 29.39% | SMA20 | -4.47% ($362.72) | Beta | 0.62 | Target Price | $434.95 |
| Payout | - | Debt/Eq | 0.4 | Earnings | 2026/8/5 | SMA50 | 2.37% ($338.49) | Rel Volume | 0.81 | Prev Close | $341.8 |
| Employees | 12000 | LT Debt/Eq | 0.34 | EPS/Sales Surpr. | 23.45% 4.95% | SMA200 | 9.04% ($317.78) | Avg Volume(3M) | 0.38M | Price | $346.51 |
| IPO | 2016/2/3 | Option/Short | Yes/Yes | Trades | 9051 | Volume | 304,397 | Change | 1.38% |
Company
ONC is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 This is a global biotech company focused on anti-cancer therapeutics. Founded in 2010 and headquartered in Basel, Switzerland, the company, which changed its name from BeiGene and trades under the ticker ONC, is a large-cap biotech holding a pipeline of BTK inhibitors and other candidates for hematologic cancers and solid tumors, making it a key name riding the wave of expansion in the global oncology drug market.
Over the past 1 year, roughly in the middle
10% below its 1-year high.
ONC makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +183.1% this year.
Tap to view numbers
The price looks about right
Trading at 60.9 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +65.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 33.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
KURE 0.09%
BBH 0.03%
FBT 0.02%
AGNG 0.02%
BGGG 0.02%It ranks #4 in the industry
Based on market cap of $36B.
ONC $36B PER 60.9
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is ONC?
ONC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ONC?
The market cap of ONC is approximately $36.1B, ranking 411 within its sector.
What is the P/E ratio of ONC?
ONC has a P/E ratio of approximately 60.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ONC?
ONC has recorded a 52-week high of $385.22 and a low of $253.95.
